A detailed history of Nine Point Two Capital LLC transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Nine Point Two Capital LLC holds 17,677 shares of ITOS stock, worth $255,255. This represents 0.08% of its overall portfolio holdings.

Number of Shares
17,677
Previous 17,677 -0.0%
Holding current value
$255,255
Previous $193,000 -0.0%
% of portfolio
0.08%
Previous 0.08%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$12.93 - $18.05 $23,700 - $33,085
-1,833 Reduced 9.4%
17,677 $234,000
Q1 2023

May 15, 2023

BUY
$13.02 - $22.62 $254,020 - $441,316
19,510 New
19,510 $265,000
Q2 2022

Aug 15, 2022

BUY
$16.57 - $35.1 $84,424 - $178,834
5,095 Added 47.71%
15,773 $324,000
Q1 2022

May 16, 2022

BUY
$31.92 - $47.45 $340,841 - $506,671
10,678 New
10,678 $343,000

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $514M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Nine Point Two Capital LLC Portfolio

Follow Nine Point Two Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nine Point Two Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nine Point Two Capital LLC with notifications on news.